Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Panacos makes progresses with HIV therapy
In the phase IIb study, HIV-infected patients failing their current antiretroviral therapy will receive oral bevirimat or placebo once daily for three months in combination with background antiretroviral
In the phase IIb study, HIV-infected patients failing their current antiretroviral therapy will receive oral bevirimat or placebo once daily for three months in combination with background antiretroviral
The phase IIa trial, to be conducted at the Royal Adelaide Hospital in Australia, will evaluate the drug primarily in patients suffering from diabetic neuropathy. The dose-escalating trial
The companies will jointly select five targets, including targets with the potential to raise “good cholesterol”, for development with PTC’s GEMS (gene expression modulation by small-molecules) technology. The
MicroRNAs (miRNAs) are a recently discovered class of natural antisense RNAs that are important in the regulation of cellular functions. These data demonstrate that antisense inhibition is a
The Saforis new drug application is partially based on a pivotal phase III trial which was completed in 326 patients with breast cancer who were receiving anthracycline-based chemotherapy
The drug, whose proposed brand name is Arxxant, reduced the risk of sustained moderate vision loss by 41% when compared to placebo in patients with moderate to severe,
HGS will retain a 13% equity interest in CoGenesys which has exclusive rights to develop and commercialize biological products based on certain human genes discovered by HGS. CoGenesys
The 12 month study is focused on examining safety as well as efficacy of the drug in patients with paroxysmal nocturnal hemoglobinuria (PNH), an acquired genetic blood disorder
Statistical significance on the primary outcome measure of the trial of change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score was not achieved, however, statistically
These data were presented at the 66th Annual Scientific Sessions of the American Diabetes Association. “These findings are important because they confirm that people who switched from rapid-acting